Tammie Wahaus serves as Chief Executive Officer of ELIAS Animal Health, a biotechnology company with Corporate headquarters in Kansas City. ELIAS is advancing a personalized, vaccine-enhanced adoptive T cell-based immunotherapy for the treatment of cancer in the veterinary sector. As founder, she has led the company formation, strategic planning, clinical development and regulatory affairs for ELIAS since 2014. She joined TVAX Biomedical (a human health biotech company) in 2012 as Chief Financial Officer and developed the animal health spin-off strategy that resulted in the formation of ELIAS. Ms. Wahaus is an experienced business leader with more than twenty-five years of experience serving in leadership roles for both public and private companies. Previously, Ms. Wahaus was an audit partner and national office advisor with Ernst & Young LLP. She also served as Global Controller and Principal Accounting Officer for GE Global Insurance Holdings and where she oversaw the global accounting and reporting operations across four continents and implemented Six Sigma Quality process management systems. She is a member of the University of Kansas Bioscience Workforce Education Board, the Kansas State University College of Business Advisory Board, and Pipeline Entrepreneurs. Ms. Wahaus is a graduate of Kansas State University (BS Business Administration, Accounting).